We have begun development of a biosimilar to BOTOX®, which would compete in the existing neuromodulator marketplace. In February 2018, we signed a collaboration and license agreement with Mylan N.V. for development and regulatory approval of a biosimilar to BOTOX, to be followed with commercialization by Mylan in the U.S., Europe, and applicable markets across the globe, post regulatory approvals.
BOTOX® is a registered trademark of Allergan, Inc.
China Market License
We recently entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., (Fosun Pharma Industrial), a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (Fosun Pharma), providing Fosun Pharma Industrial with the exclusive rights to develop and commercialize our proprietary DaxibotulinumtoxinA for Injection (DAXI) in mainland China, Hong Kong and Macau (the Territory).
If you are interested in pursuing a corporate partnership please contact us by filling out the form below: